Analyst Price Target is $66.75
▲ +297.56% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Arcturus Therapeutics in the last 3 months. The average price target is $66.75, with a high forecast of $86.00 and a low forecast of $48.00. The average price target represents a 297.56% upside from the last price of $16.79.
Current Consensus is
Buy
The current consensus among 7 investment analysts is to buy stock in Arcturus Therapeutics. This rating has held steady since October 2023, when it changed from a Hold consensus rating.
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Read More